Spyre Therapeutics
SYREPharmaceutical Preparations · Avg daily volume 1.3M · fiscal year ends Dec$96.56−2.40−2.43%Volume 661,127−50% vs avg
10-day20-day50-day200-dayRS line vs S&P 500▲ earnings filed, EPS vs a year ago
2026-10-30O 96.78 H 98.96 L 94.68 C 96.56 (−2.43%)Vol 661,12710 93.9020 88.1650 90.06200 73.22RS line 12.8RS rating 99
| FY (Dec) | EPS $ | Chg | High | Low |
|---|---|---|---|---|
| 2020 | -912.00 | – | – | – |
| 2021 | -600.00 | +34% | – | – |
| 2022 | -594.00 | +1% | – | – |
| 2023 | 13.76 | +102% | – | – |
| TTM | – | 110 | 21 |
Ratings & facts
RS Rating99 ▲1
Days at RS 90+23
Setup checks3 / 3
EPS chg, last qtr–
EPS acceleratingno
Sales chg, last qtr–
P/E (last 4 qtrs)–
Mkt cap$8.51B
Off 52-wk high-12.4%
Quarterly earnings
Latest filing: 10-Q, 2026-05-05Sep ’22FQ3 ’22
Dec ’22Q4FQ4 ’22
Mar ’23FQ1 ’23
Jun ’23FQ2 ’23
Sep ’23FQ3 ’23
Dec ’23Q4FQ4 ’23
Mar ’24FQ1 ’24
Jun ’24FQ2 ’24
Sep ’24FQ3 ’24
Mar ’26FQ1 ’26
EPS
EPS
−$114.00
−$108.00
−$120.00
$40.14
$0.86
−$0.89
$0.72
$0.59
$1.06
−$0.74
% chg
+39%
+42%
+46%
+125%
+101%
+99%
+101%
−99%
+23%
–
Sales
174,000
168,000
198,000
688,000
0
–
0
0
0
–
% chg
−88%
−95%
−86%
+10%
−100%
–
−100%
−100%
–
–
Filed
11/03
03/02
05/11
08/11
11/09
02/29
05/09
08/07
11/07
05/05
EPS growth ≥ 25%0–25%fallingno comparison
Source: SEC EDGAR 10-Q and 10-K filings, loaded the first time a stock is opened and refreshed daily. Q4 = full year minus the first three quarters. Growth from a loss is measured against the size of the loss (−$1 → $2 = +300%). Analyst estimates are not in EDGAR.